[go: up one dir, main page]

MX2015008481A - Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. - Google Patents

Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.

Info

Publication number
MX2015008481A
MX2015008481A MX2015008481A MX2015008481A MX2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A MX 2015008481 A MX2015008481 A MX 2015008481A
Authority
MX
Mexico
Prior art keywords
compounds
heterobicyclo
quinazolin
triazolo
ami
Prior art date
Application number
MX2015008481A
Other languages
English (en)
Other versions
MX370017B (es
Inventor
Dong Xiao
Andrew Stamford
Paul Tempest
Xianhai Huang
Rongze Kuang
Jae-Hun Kim
Yeon-Hee Lim
Junying Zheng
Walter Won
Amjad Ali
Edward Metzger
Timothy J Henderson
Younong Yu
Heping Wu
Nicolas Zorn
Christopher Boyce
Michael Man-Chu Lo
Pauline Ting
Gioconda V Gallo
Qiaolin Deng
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2015008481A publication Critical patent/MX2015008481A/es
Publication of MX370017B publication Critical patent/MX370017B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen compuestos de fórmula GI: (ver Fórmula) en donde "RG3" "Rd1", a "Rd4","n","m","p", "W","X", "Y" y "Z" son como se definen en la presente, cuyos compuestos son antagonistas del receptor A2A; también se describen en la presente usos de los compuestos descritos en la presente como antagonistas del receptor A2A en el tratamiento potencial o prevención de trastornos y enfermedades neurológicas en las cuales están involucrados los receptores A2A; en la presente también se describen composiciones farmacéuticas que comprenden estos compuestos y usos de estas composiciones farmacéuticas.
MX2015008481A 2012-12-28 2013-12-20 Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a. MX370017B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
PCT/CN2013/076853 WO2014101373A1 (en) 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Publications (2)

Publication Number Publication Date
MX2015008481A true MX2015008481A (es) 2015-09-23
MX370017B MX370017B (es) 2019-11-28

Family

ID=51019745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008481A MX370017B (es) 2012-12-28 2013-12-20 Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.

Country Status (22)

Country Link
US (2) US9708347B2 (es)
EP (1) EP2945632B1 (es)
JP (1) JP6306049B2 (es)
KR (1) KR102165113B1 (es)
AU (1) AU2013370977B2 (es)
BR (1) BR112015015468B8 (es)
CA (1) CA2896056C (es)
CY (1) CY1120258T1 (es)
DK (1) DK2945632T3 (es)
ES (1) ES2667477T3 (es)
HR (1) HRP20180678T1 (es)
HU (1) HUE037950T2 (es)
LT (1) LT2945632T (es)
ME (1) ME03034B (es)
MX (1) MX370017B (es)
NO (1) NO2945632T3 (es)
PL (1) PL2945632T3 (es)
PT (1) PT2945632T (es)
RS (1) RS57162B1 (es)
RU (2) RU2671628C2 (es)
SI (1) SI2945632T1 (es)
WO (3) WO2014101120A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
JP2020506885A (ja) 2017-01-13 2020-03-05 江蘇恒瑞医薬股▲ふん▼有限公司 １，２，４−トリアジン−３−アミン誘導体、その製造方法、および医薬におけるその使用
WO2018153373A1 (zh) 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr抑制剂及其应用
CN109963854B (zh) 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
CA3077267C (en) * 2017-09-28 2021-02-16 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused heteroaryl ring derivatives useful as a2a receptor inhibitor
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
CA3089159A1 (en) 2018-02-06 2019-08-15 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
MA55142A (fr) 2018-11-20 2022-02-23 Merck Sharp & Dohme Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
EP3883576B1 (en) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US11312719B2 (en) 2018-11-30 2022-04-26 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
BR112021010273A2 (pt) 2018-11-30 2021-08-17 Merck Sharp & Dohme Corp. derivados de amino triazolo quinazolina substituídos em 7, 8 e 10 como antagonistas do receptor de adenosina, composições farmacêuticas e seu uso
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CA3102364A1 (en) 2019-03-26 2020-10-01 Novel Pharma Inc. Long-acting fatty acid-conjugated gnrh derivatives and pharmaceutical compositions containing same
DK4097099T3 (da) 2020-02-07 2024-07-15 Gasherbrum Bio Inc Heterocyckliske GLP1-agonister
EP4185296A4 (en) * 2020-07-24 2025-03-05 Merck Sharp & Dohme LLC DUAL ADENOSINE A2A RECEPTOR AND A2B RECEPTOR ANTAGONISTS FOR IMMUNO-ONCOLOGY
EP4185297A4 (en) * 2020-07-24 2024-08-28 Merck Sharp & Dohme LLC Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
CN112159411A (zh) * 2020-10-15 2021-01-01 南京工业大学 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
EP0181282A1 (de) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
WO1995035107A1 (en) 1994-06-20 1995-12-28 Smithkline Beecham Corporation Endothelin receptor antagonists
US5571775A (en) * 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US5929106A (en) 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
MXPA02011625A (es) 2000-05-26 2003-03-27 Schering Corp Antagonistas receptores de adenosina a2a.
EP1293029A1 (en) * 2000-06-20 2003-03-19 Alexander Ellison Rees Electrical drive line
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
NZ540493A (en) * 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
ATE418555T1 (de) * 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2339502T3 (es) 2006-06-26 2010-05-20 Schering Corporation Antagonistas del receptor a2a de adenisina.
US20090062253A1 (en) 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2011060207A1 (en) * 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Also Published As

Publication number Publication date
RU2671628C2 (ru) 2018-11-06
CY1120258T1 (el) 2019-07-10
HRP20180678T1 (hr) 2018-06-01
PT2945632T (pt) 2018-05-22
US9708347B2 (en) 2017-07-18
BR112015015468A2 (pt) 2017-07-11
EP2945632B1 (en) 2018-03-07
AU2013370977A1 (en) 2015-07-09
PL2945632T3 (pl) 2018-07-31
DK2945632T3 (en) 2018-05-22
CA2896056A1 (en) 2014-07-03
RU2018136104A (ru) 2018-11-21
US20170197991A1 (en) 2017-07-13
ME03034B (me) 2018-10-20
BR112015015468B8 (pt) 2023-04-25
SI2945632T1 (en) 2018-05-31
WO2014101120A1 (en) 2014-07-03
EP2945632A1 (en) 2015-11-25
RS57162B1 (sr) 2018-07-31
JP2016504363A (ja) 2016-02-12
HUE037950T2 (hu) 2018-09-28
JP6306049B2 (ja) 2018-04-04
WO2014105666A1 (en) 2014-07-03
RU2015131148A (ru) 2017-02-03
US10011615B2 (en) 2018-07-03
KR102165113B1 (ko) 2020-10-13
AU2013370977B2 (en) 2017-12-14
CA2896056C (en) 2020-11-10
MX370017B (es) 2019-11-28
US20150361098A1 (en) 2015-12-17
RU2018136104A3 (es) 2022-04-05
LT2945632T (lt) 2018-05-25
NO2945632T3 (es) 2018-08-04
EP2945632A4 (en) 2016-09-14
ES2667477T3 (es) 2018-05-11
WO2014101373A1 (en) 2014-07-03
BR112015015468B1 (pt) 2021-10-26
KR20150100879A (ko) 2015-09-02

Similar Documents

Publication Publication Date Title
MX2015008481A (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2015KN00414A (es)
TN2015000250A1 (en) Novel benzimidazole derivatives as ep4 antagonists
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
IN2014DN07384A (es)
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
WO2013163190A8 (en) Dna-pk inhibitors
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
AU2012357747A8 (en) TRPM8 antagonists
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.

Legal Events

Date Code Title Description
FG Grant or registration